0HB0.LAgios Pharmaceuticals, Inc.

About

Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of treatments within cellular metabolism and associated biological domains. Its lead product, PYRUKYND (mitapivat), serves as an activator for both healthy and various mutated forms of the pyruvate kinase (PK) enzyme, targeting the management of hemolytic anemias. Additionally, AG-946, an investigational compound, is currently undergoing Phase I clinical evaluation for hemolytic anemias and other conditions. Established in 2007, Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

www.agios.com

Key Statistics

Market Cap

2.22B

EPS

-7.12

Dividend Yield

0.00%

Beta

0.59

P/B

1.32

Return on Equity

-34.6%

Sector

Healthcare

Industry

Biotechnology

CEO

Brian Goff

Employees

486

IPO Date

2018-01-29

Country

US